Vasovagal SyncopeProcedure
What this study is
The CNA-FWRD Registry is an international prospective observational multicenter registry of patients with symptomatic vasovagal syncope and bradyarrhythmias managed under routine care by medical therapy and radiofrequency catheter ablation of ganglionated plexi or permanent pacemaker implantation.
What's being tested
- Ablation procedure
Intervention · PROCEDURE
Cardioneuroablation procedure or permanent pacemaker placement
Study details
- Official title
- Cardioneuroablation for the Management of Patients With Recurrent Vasovagal Syncope and Symptomatic Bradyarrhythmias: The CNA-FWRD Registry
- Sponsor
- Rush University Medical Center
- Conditions
- Vasovagal Syncope · AV Block-2Nd Degree-Type 1 · Sinus Pause
- Enrolling
- 300 people
- Starts
- 2024-08-01
- Est. completion
- 2027-04-30
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 60 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Symptomatic vasovagal syncope or symptomatic bradyarrhythmia refractory to behavioral and medical measures
- Age < 60 years
You can't join if
- Age > 60 years
- Intra-/infra-Hisian AV block
- Intrinsic sinus node disease
- History of supraventricular tachycardia
- History of ventricular tachycardia
- Presence of structural heart disease related
- Prior history of catheter ablation
- Presence of inheritable arrhythmic conditions
- Orthostatic hypotension on HUTT test
- Abnormal thyroid function levels
- Proven indication for permanent pacemaker implantation
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openRush University Medical Centert
Chicago, Illinois, United States
- Henry D Huang, MD · Contact312-942-5020henry_d_huang@rush.edu
Recruiting
Study team
Sponsor
Rush University Medical Center
Study ID CNA-FWRD
Study chair
Tolga Aksu, MD
Yepedite University
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.